F52.21 Insurance Policy Changes

ICD-10 F52.21 is officially defined as "Male erectile disorder." code F52.21 is referenced in 8 tracked payer policy changes from Excellus BlueCross BlueShield, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code F52.21 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Oct 22, 2026Medium impact
Erectile Dysfunction 7.01.30
Excellus BlueCross BlueShield medical policy 7.01.30 sets the criteria for treating erectile dysfunction (ED). Treatment is considered medically appropriate when symptoms have lasted more than six months and one of the listed modalities applies: oral drug therapy, intracavernous injection therapy, the transurethral MUSE system, vacuum constriction devices, penile prosthetic implants, or arterial revascularization. Treatment may start before six months for an acute event such as penile trauma or radical pelvic surgery, or for drug-induced ED caused by treatment of a co-morbid condition. The 10/22/26 revision is an annual review, and the policy intent is unchanged.
Aetna · Identified Oct 2, 2026Medium impact
Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2026-09-14)
Aetna clinical policy bulletin 0649 (reviewed September 14, 2026) considers extracorporeal shock-wave therapy medically necessary only for calcific tendinopathy of the shoulder that has lasted at least 6 months, has a calcium deposit of 1 cm or more, and has not responded to conservative care. It lists many other musculoskeletal, pain, wound and scar indications as experimental or not covered. The source gives a review date but no effective date, so confirm current applicability before changing workflows.
Aetna · Identified Aug 14, 2026Medium impact
Pudendal Nerve Decompression (CPB 0805, reviewed 2025-11-20)
Aetna clinical policy bulletin 0805 considers pudendal nerve decompression experimental, investigational, or unproven for indications including chronic pelvic pain, interstitial cystitis, penile numbness and erectile dysfunction, persistent genital arousal disorder, pudendal neuralgia, and vulvodynia. The policy also considers pudendal nerve hydrodissection for chronic pelvic pain syndrome and urinary incontinence, and pudendal neurolysis for persistent genital arousal disorder and pudendal nerve entrapment syndrome, experimental, investigational, or unproven. The policy does not apply to pudendal nerve blocks used in obstetrics and other operative procedures.
Aetna · Identified Aug 13, 2026Medium impact
Erectile Dysfunction and Peyronie's Disease (CPB 0007, reviewed 2026-07-29)
Aetna considers the diagnosis and treatment of erectile dysfunction medically necessary under the criteria in its policy, including self-administered injectable medications, the external penile vacuum pump as a physician-prescribed durable medical equipment alternative to other therapies, and implantable penile prostheses when the documented criteria are met. Surgical correction of Peyronie's disease, such as plaque excisions, venous graft patching, tunica plication or the Nesbit tuck, is medically necessary for members who have the condition for 12 or more months with significant morbidity and have failed conservative medical treatment. Many other treatments, including extracorporeal shock wave therapy and testosterone injection for Peyronie's disease and stem cell therapy for erectile dysfunction, are considered experimental, investigational, or unproven.
Aetna · Identified Nov 2, 2026Low impact
Pudendal Nerve Decompression (CPB 0805, reviewed 2026-10-28)
Aetna's clinical policy bulletin 0805 on pudendal nerve decompression was reviewed on 10/28/2026. It treats pudendal nerve decompression, hydrodissection and neurolysis as experimental, investigational or unproven for chronic pelvic pain, pudendal neuralgia, interstitial cystitis, penile numbness and erectile dysfunction, persistent genital arousal disorder and vulvodynia, and it lists three related CPT codes as not covered for those indications. The source does not state an effective date for a change or describe a coverage change in this review.
Aetna · Identified Aug 15, 2026Low impact
Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2025-10-02)
This is Aetna Clinical Policy Bulletin 0649, reviewed October 2, 2025 and first found by PolicyChanges in August 2026, so it is historical material and the current version should be confirmed before acting. Aetna covers extracorporeal shock-wave therapy only for calcific tendinopathy of the shoulder with a calcium deposit of at least 1 cm lasting 6 months or more after conservative care has failed, and lists dozens of other musculoskeletal, wound and medical uses as experimental, investigational or unproven.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA11.079e, Evaluation and Treatment of Erectile Dysfunction (ED)
Independence Blue Cross reissued MA11.079e on 01/21/2026 to communicate the Company's continuing position on ED evaluation and treatment. The policy adds CPT code 0864T (effective 01/02/2024) and now applies to New Jersey Medicare Advantage lines of business (effective 01/01/2024). No substantive coverage criteria changes were made in the most recent reissuance.
Independence Blue Cross · Identified Jun 19, 2026Low impact
11.11.01k, Evaluation and Treatment of Erectile Dysfunction (ED)
Independence Blue Cross reissued Policy 11.11.01k on 01/21/2026 with no substantive changes to erectile dysfunction evaluation and treatment coverage. The policy continues to cover medically necessary diagnostic procedures, vacuum constriction devices, penile prosthetic implants, and penile revascularization under specific clinical criteria. CPT code 0864T was previously added on 01/02/2024 as part of a CPT code update.

Watch F52.21

Get one email when a payer policy names F52.21, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code F52.21?

There are 8 tracked policy changes affecting code F52.21, including updates from Excellus BlueCross BlueShield, Aetna, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code F52.21?

Payers that have issued tracked updates for code F52.21 include: Excellus BlueCross BlueShield, Aetna, Independence Blue Cross.

How do I get notified when code F52.21 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code F52.21. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code F52.21?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Erectile Dysfunction 7.01.30

Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2026-09-14)

Pudendal Nerve Decompression (CPB 0805, reviewed 2025-11-20)

Erectile Dysfunction and Peyronie's Disease (CPB 0007, reviewed 2026-07-29)

Pudendal Nerve Decompression (CPB 0805, reviewed 2026-10-28)

Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2025-10-02)

MA11.079e, Evaluation and Treatment of Erectile Dysfunction (ED)

11.11.01k, Evaluation and Treatment of Erectile Dysfunction (ED)

What insurance policy changes affect code F52.21?

Which payers have updated policy for code F52.21?

How do I get notified when code F52.21 policy changes?

Why do payers change policies for code F52.21?